First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma
2020 ◽
Vol 26
(10)
◽
pp. 2308-2317
◽
Keyword(s):
Phase I
◽
Keyword(s):